

SUBSTITUTE SHEET (RULE 26)

5' / 1 5

FIG. 3A







FIG. 3B



SUBSTITUTE SHEET (RULE 26)

6 / 15



SUBSTITUTE SHEET (RULE 26)

7 / 15

FIG. 5A





FIG. 5B



8 / 15

1 MVAPRPLRRVVLFFYQGKLCMAGNFWQSSHYLQWILDKQD

41 LLKERQKDLKFLSEEEYWKLQIFFTNVIQALGEHLKLRQQ

81 VIATATVYFKRFYARYSLKSIDPVLMAPTCVFLASKVEEF

121 GVVSNTRLIAAATSVLKTRFSYAFPKEFPYRMNHILECEF

161 YLLELMDCCLIVYHPYRPLLQYVQDMGQEDMLLPLAWRIV

201 NDTYRTDLCLLYPPFMIALACLHVACVVQQKDARQWFAEL

241 SVDMEKILEIIRVILKLYEQWKNFDERKEMATILSKMPKP

281 KPPPNSEGEQGPNGSQNSSYSQS/////////////////
-----RNSLSDKAIYCKVTVKESRVQMEVRTLATANLKT
321 /////
FRRIP

FIG.6

SUBSTITUTE SHEET (RULE 26)

9 / 15

FIG. 7A

```
1 gagcggttacggagggctgggtctatggtcgtccggtccgctcc-----  
51 gccgcgtggtgctttttatcagggcaagctgtgtccatggcaggaac-----  
101 ttttggcagagctcccactatttgcaatggattttggataaacaagatct-----  
151 gttgaaggagcgccaaaaggatttaaagtttctctcagaggaagaatat-----  
201 ggaagttacaataattttttacaaatgttatccaagcattaggtgaacat-----  
251 cttaaatgaagacaacaagttattgccactgctacggtatatattcaagag-----  
301 attctatgccaggatttctctgaaaagtagatcctgtattaatggctc-----
```

10 / 15

FIG. 7B

351 ctacatgtgtgttttttggcatccaagtagaggaatttggagtagtttca

401 aatacaagattgattgctgctgctacttctgtattaaaaactagattttc

451 atatgcctttccaaaagggaatttccttataggatgaatcatatattagaat

501 gtgaattctatctgttagaactaatggattgttgcttgatagtgatcat

551 ccttatagaccctttgctccagtatgtgcaggacatggccaagaagacat

601 gttgcttcccccttgcatggaggatagtgatgataacctacagaacggatc

651 tttgcctactgtatccctcctttcatgatagcttttagcttgccatcatgta

SUBSTITUTE SHEET (RULE 26)

11 / 15

FIG.7C

701 gcctgtgtgtgtacagcagaaagatgccaggcaatggtttgctgagctttc

751 tgtggatatggaaaagattttggaaataatcagggttattttaaaactat

801 atgagcagtggaaagaatttcgatgagagaaaaagagatggcaaccattctt

851 agtaagatgccaaaaccacccacctccaaaca////////////////
-----gaaattccctgagtga

901 ////////////////////////////gtgaaggagagcagggtccaaa
taaggcaataatctattgcaaagtact-----

951 tggaagtcagaactctagctacagccaatcttaaaacatcccgaagaatt

1001 ccatag

1 2 / 1 5

1 MVAPRPLRRVVLFFYQGKLCMAGNFWQSSHYLQWILDKQD

41 LLKERQKDLKFLSEEEYWKLQIFFTNVIQALGEHLKLRQQ

81 VIATATVYFKRFYARYSLKSIDPVLMAPTCVFLASKVEEF

121 GVVSNTRLIAAATSVLKTRFSYAFPKEFPYRMNHILECEF

161 YLLELM//////////DCCLIVYHPYRPLLQYVQDMG
-----VSKSSVINRLKHF*
201 QEDMLLPLAWRIVNDTYRTDLCLLYPPFMIALACLHVACV
241 VQOKDARQWFAELSDMEKILEIIRVILKLYEQWKNFDER
281 KEMATILSKMPKPKPPPNSEGEQGPNGSQNSSYSQS

FIG.8

SUBSTITUTE SHEET (RULE 26)

13 / 15

1 gagcgcggttaccggacgggctgggtctatggtcgctccgcgggccgctcc

51 gccgctgggtgcttttttatcagggcaagctgtgttccatggcaggggaac

101 ttttggcagagctcccactatttgcaatggattttggataaacaagatct

151 gttgaaggagcgccaaaaggatttaaagtctctctcagaggaagaatatt

201 ggaagttacaaatattttttacaaatgttatccaagcattaggtgaacat

251 cttaaattaagacaacaagttattgccactgctacgggtatatttcaagag

301 attctatgccaggtattctctgaaaagtatagatcctgtattaatggctc

351 ctacatgtgtgtttttggcatccaaagtagaggaatttggagtagtttca

401 aatacaagattgattgctgctgctacttctgtattaaaaactagattttc

451 atatgcctttccaaaggaatttccttataggatgaatcatatattagaat

Exon 7

501 gtgaattctatctgttagaactaatg/////////////////////////
-----gtaagtaaattcttctgtgattaat

/////////////////////////
agattaaaacattttttaattaaatgaagttggaaattatttaaagaaat

/////////////////////////
gatttttagagaggtacatttttaaaccatccacctaatatgtgatgggtga

/////////////////////////
aatcatggtagcctattttatattagcacctagagtctctctgaagcctgt

FIG.9A

SUBSTITUTE SHEET (RULE 26)

15 / 15

/////////
tttacatttctata

Exon 9

590 ggaggatagtgaaatgatacctacagaacggatc

622 ttgcctactgtatcctcctttcatgatagctttagcttgcctacatgta

673 gcctgtgttgtagcagcagaaagatgccaggcaatgggttgctgagctttc

724 tgtggatatggaaaagattttggaaataatcagggttattttaaaactat

775 atgagcagtggagaattttcgatgagagaaaagagatggcaaccattctt

826 agtaagatgccaaaaccaaaccacctccaaacagtcaaggagagcaggg

877 tccaaataaggcaataatctattgcaaagttacttggaagtcagaactct

928 agctacagccaatcttaa

FIG.9C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/09709

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/465 C07K14/47 C07K16/18 C12N5/10
A01K67/027 A61K38/17 A61K31/70 A61K48/00 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A01K A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL Database entry GG40873; Accession number U40873; 20.11.1995; Li H. et al.: 'Gallus gallus cyclin C mRNA.' XP002039161 see abstract	22,23
A	CELL, vol. 66, 1991, pages 1197-1206, XP002039130 LEW D.J. ET AL.: "Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast." cited in the application see the whole document, especially Fig. 3A and from page 1199, right column, last paragraph to page 1200, right column, bottom line	1-32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

2 September 1997

Date of mailing of the international search report

16.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/09709

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 666 270 A (BRISTOL-MYERS SQUIBB COMPANY) 9 August 1995 see the whole document, especially page 4, lines 46-58 and page 7, lines 44-57 ---	1-32
A	WO 93 24514 A (MITOTIX) 9 December 1993 see the whole document, especially page from 6, line 27 to page 7, line 14 and from page 20, line 16 to page 21, line 11 ---	1-32
A	PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 8871-8875, XP002039131 TASSAN J.-P. ET AL.: "Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C." cited in the application ---	1-32
A	SCIENCE, vol. 240, 1988, pages 1544-1546, XP002039132 JASKULSKI D. ET AL.: "Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin." see the whole document ---	21,27
P,X	ONCOGENE, vol. 13, no. 4, 15 August 1996, pages 705-712, XP002039133 LI H. ET AL.: "Alternatively spliced cyclin C mRNA is widely expressed, cell cycle regulated, and encodes a truncated cyclin box." see the whole document -----	1-32

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Please see Further Information sheet enclosed.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/ 09709

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Remark : Although claim 27 and claims 28-30 partially, as far as they concern an in vivo method, are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

... on patent family members

Application No

PCT/US 97/09709

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0666270 A	09-08-95	US 5625031 A	29-04-97
		CA 2140379 A	09-08-95
		JP 7316196 A	05-12-95

WO 9324514 A	09-12-93	NONE	

Form PCT/ISA/210 (patent family annex) (July 1992)

